Notch signaling: an emerging therapeutic target for cancer treatment (Q26784068)

1

0 references

Hua Wu

2

0 references

Hanxiao Xu

3

0 references

Huihua Xiong

4

0 references

Qian Chu

5

0 references

Shiying Yu

6

0 references

Gen Sheng Wu

7

0 references

Kongming Wu

Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival

8

0 references

language of work or name

English

0 references

publication date

1 December 2015

0 references

published in

Cancer Letters

0 references

volume

369

0 references

issue

1

0 references

page(s)

20-7

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A Notch-dependent transcriptional hierarchy promotes mesenchymal transdifferentiation in the cardiac cushion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Constitutive Notch2 signaling induces hepatic tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

γ-Secretase Inhibitor, DAPT Inhibits Self-renewal and Stemness Maintenance of Ovarian Cancer Stem-like Cells In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Jagged/Notch signalling is required for a subset of TGFβ1 responses in human kidney epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A phase II study of RO4929097 in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Targeting notch signaling pathway in cancer: clinical development advances and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Mechanisms of epigenetic and cell-type specific regulation of Hey target genes in ES cells and cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Therapeutic antibody targeting of individual Notch receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch inhibition allows oncogene-independent generation of iPS cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch signalling in solid tumours: a little bit of everything but not all the time

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Regulatory networks defining EMT during cancer initiation and progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Therapeutic modulation of Notch signalling--are we there yet?

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4).

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Alterations of the Notch pathway in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Slug is a direct Notch target required for initiation of cardiac cushion cellularization

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

The Notch signaling pathway as a mediator of tumor survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Chromosome 19 translocation, overexpression of Notch3, and human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Delta-like ligand 4-notch blockade and tumor radiation response

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus promotes angiogenesis through targeting notch signaling effector Hey1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

New, tolerable γ-secretase inhibitor takes desmoid down a notch

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

NOTCH mutations: multiple faces in human malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Frequency and distribution of Notch mutations in tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Aspartate β-Hydroxylase expression promotes a malignant pancreatic cellular phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021

GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CANLET.2015.07.048

7 January 2021